Comparison of Success Rates of Pleurodesis with Talc, and Holmium-YAG Laser in the Patients with Malignant Pleural Effusion

Objective: We aimed to investigate the efficacy of Holmium-yttrium aluminum garnet (Ho-YAG) laser using video assisted thoracoscopic surgery (VATS) and compare it with the talcslurry pleurodesis in patients with malignant pleural effusion (MPE).Methods: A total of 51 patients with MPE were included. Patients were divided into two groups. In the laser group, pleurodesis was attempted using Ho-YAG laser through auniportal VATS in 30 patients; in the talc group, pleurodesis was attempted using talc slurry through a small bore chest tube in 21 patients. The success rate of pleurodesis was evaluated using chest X-ray and/or thorax computed tomography obtained at the second month following pleurodesis and was graded as total success, partial success, or failure.Results: In the laser group, pleurodesis was a total success in 19 (63%) patients and partial in 7 (23%) patients. The volume of pleural effusion drained postoperatively was significantly different between the success subgroups (total success subgroup vs. failure subgroup, p=0.000; partial success subgroup vs. failure subgroup, p=0.001). In the talc group, pleurodesis was a total success in 11 (52%) patients and partial in 6 (29%) patients. The success rates of pleurodesis between the talc and laser groups showed no significant difference (p=0.725).Conclusion: The use of Ho-YAG laser through VATS is a safe and effective option for pleurodesis in the management of MPE. However, there is no difference between Ho-YAG laser and talc slurry pleurodesis in terms of procedure success rates.

PDF

___

1. Mithiran H, Leow L, Ong K, Liew T, Siva D, Liang S, et al. Video-Assisted Thoracic Surgery (VATS) Talc Pleurodesis Versus Pleurectomy for Primary Spontaneous Pneumothorax: A Large Single-Centre Study with No Conversion. World J Surg 2019 Apr 9. doi: 10.1007/s00268-019-05001-2. [CrossRef]
2. Haas AR, Sterman DH, Musani AI. Malignant pleural effusions: management options with consideration of coding, billing, and a decision approach. Chest 2007; 132: 1036-41. [CrossRef]
3. Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 2000; 117: 73-8. [CrossRef]
4. Tan C, Sedrakyan A, Browne J, Swift S, Treasure T. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 2006; 29: 829-38. [CrossRef]
5. Aboudara M, Maldonado F. Update in the Management of Pleural Effusions. Med Clin North Am 2019; 103: 475-85. [CrossRef]
6. Galbis JM, Mata M, Guijarro R, Esturi R, Figueroa S, Arnau A. Clinical-therapeutic management of thoracoscopy in pleural effusion: a groundbreaking technique in the twenty-first century. Clin Transl Oncol 2011; 13: 57-60. [CrossRef]
7. Perin B, Zaric B, Jovanovic S, Matijasevic J, Stanic J, Kopitovic I, et al. Patient-related independent clinical risk factors for early complications following Nd: YAG laser resection of lung cancer. Ann Thorac Med 2012; 7: 233-7. [CrossRef]
8. Torre M, Grassi M, Nerli FP, Maioli M, Belloni PA. Nd-YAG laser pleurodesis via thoracoscopy. Endoscopic therapy in spontaneous pneumothorax Nd-YAG laser pleurodesis. Chest 1994; 106: 338-41. [CrossRef]
9. Javanmard B, Fallah Karkan M, Razzaghi MR, Ghiasy S, Ranjbar A, Rahavian A. Surgical Management of Vesical Stones in Children: A Comparison Between Open Cystolithotomy, Percutaneous Cystolithotomy and Transurethral Cystolithotripsy With Holmium-YAG Laser. J Lasers Med Sci 2018; 9: 183-7. [CrossRef]
10. Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ; BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65(Suppl 2): ii32-40. [CrossRef]
11. Kahrom H, Aghajanzadeh M, Asgari MR, Kahrom M. Efficacy and Safety of Povidone-iodine Pleurodesis in Malignant Pleural Effusions. Indian J Palliat Care. 2017; 23: 53-6. [CrossRef]
12. Agarwal R, Aggarwal AN, Gupta D. Efficacy and safety of iodopovidone pleurodesis through tube thoracostomy. Respirology 2006; 11: 105-8. [CrossRef]
13. Light RW. Counterpoint: should thoracoscopic talc pleurodesis be the first choice management for malignant pleural effusion? No. Chest 2012; 142: 17-9. [CrossRef]
14. Dresler CM, Olak J, Herndon JE 2nd, Richards WG, Scalzetti E, Fleishman SB, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127: 909-15. [CrossRef]
15. Lee P. Point: Should thoracoscopic talc pleurodesis be the first choice management for malignant effusion? Yes. Chest 2012; 142: 15-7. [CrossRef]
16. Fitzgerald DB, Koegelenberg CFN, Yasufuku K, Lee YCG. Surgical and non-surgical management of malignant pleural effusions. Expert Rev Respir Med 2018; 12: 15-26. [CrossRef]
17. Ferrer J, Roldán J, Teixidor J, Pallisa E, Gich I, Morell F. Predictors of pleural malignancy in patients with pleural effusion undergoing thoracoscopy. Chest 2005; 127: 1017-22. [CrossRef]
18. Bresticker MA, Oba J, LoCicero J, 3rd, Greene R. Optimal pleurodesis: a comparison study. Ann Thorac Surg 1993; 55: 364-6. [CrossRef]
19. Xia H, Wang XJ, Zhou Q, Shi HZ, Tong ZH. Efficacy and safety of talc pleurodesis for malignant pleural effusion: a meta-analysis. PLoS One 2014; 9: e87060. [CrossRef]
20. Davies HE, Lee YC. Management of malignant pleural effusions: questions that need answers. Curr Opin Pulm Med 2013; 19: 374-9. [CrossRef]
21. Maskell NA, Lee YC, Gleeson FV, Hedley EL, Pengelly G, Davies RJ. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004; 170: 377-82. [CrossRef]
22. Wu YB, Xu LL, Wang XJ, Wang Z, Zhang J, Tong ZH, et al. Diagnostic value of medical thoracoscopy in malignant pleural effusion. BMC Pulm Med 2017; 17: 109. [CrossRef]
23. Arapis K, Caliandro R, Stern JB, Girard P, Debrosse D, Gossot D. Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients. Surg Endosc 2006; 20: 919-23. [CrossRef]
24. Cardillo G, Facciolo F, Carbone L, Regal M, Corzani F, Ricci A, et al. Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions. Eur J Cardiothorac Surg 2002; 21: 302-5. [CrossRef]
25. Agarwal R, Aggarwal AN, Gupta D. Diagnostic accuracy and safety of semirigid thoracoscopy in exudative pleural effusions: a meta-analysis. Chest 2013; 144: 1857-67. [CrossRef]
26. de Campos JR, Vargas FS, de Campos Werebe E, Cardoso P, Teixeira LR, Jatene FB, et al. Thoracoscopy talc poudrage : a 15-year experience. Chest 2001; 119: 801-6. [CrossRef]
27. Nour Moursi Ahmed S, Saka H, Mohammadien HA, Alkady O, Oki M, Tanikawa Y, et al. Safety and Complications of Medical Thoracoscopy. Adv Med 2016; 2016: 3794791. [CrossRef]